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ABSTRACT
Background: High-grade prostatic intraepithelial neoplasia (HGPIN) is the 
precursor or premalignant form of prostate cancer. At least 30% patients with a 
confirmed HGPIN will develop prostate cancer within 1 year after repeated biopsy. 
HGPIN patients are the appropriate at-risk population for chemoprevention strategies 
investigation against prostate cancer. However the commonly used chemoprevention 
agents that targeted on hormonal imbalance or lifestyle-related factors showed varied 
results in HGPIN patients. 
Methods: Literature searches were conducted in PubMed, EMBASE and Cochrane 
library according to Cochrane guidelines before January 31st, 2017. Direct meta-
analysis were performed to summarize the efficacy of candidate chemopreventative 
agents Dutasteride, Flutamide, Toremifene, Selenium, Green tea components, 
Lycopene and natural food products combination. Adjusted indirect meta-analyses 
were employed to compare the relative efficacy of these candidate chemoprevention 
agents head-to-head. 
Results: The overall incidence of prostate cancer in HGPIN was slightly 
decreased by chemoprevention agents (25.7% vs 31.5%, RR = 0.92, 95% CI: 0.83-
1.03, P = 0.183), with minor heterogeneity (I2 = 22.3%, 𝟀2 = 15.08, P = 0.237), but 
without statistical significance. Subgroup analysis showed that green tea catechins 
significantly decreased prostate cancer in HGPIN patients (7.60% vs 23.1%, RR = 
0.39, 95% CI: 0.16-10.97, P P = 0.044), with moderate heterogeneity (I2 = 47.9%, 𝟀2 
= 1.92, P = 0.166). The adjusted indirect meta-analysis favored green tea catechins 
over other chemoprevention agents, and significantly when compared to natural food 
products combination (RR = 0.355, 95% CI: 0.134-0.934).
Conclusion: The overall efficacy of chemoprevention agents in HGPIN patients is 





Prostate cancer is the second most common cancer 
and the fifth leading cause of cancer-related death in 
men worldwide [1]. It is urgent to develop effective 
chemoprevention agents that are expected to decrease 
prostate cancer risk, delay or prevent surgery or chemo-
radiotherapy, improve quality of life and decrease the 
frequency of invasive surveillance procedures [2, 3]. 
High-grade prostatic intraepithelial neoplasia (HGPIN) 
is considered as the precursor or premalignant form of 
prostate cancer with cytological changes similar to those 
in invasive prostate [2, 3]. HGPIN is diagnosed with 
atypical secretory luminal cells present by preexisting 
ducts and acini [4]. At least 30% patients with a confirmed 
HGPIN will develop prostate cancer within 1 year [5, 6]. 
Therefore, HGPIN patients are the appropriate at-risk 
population for chemoprevention strategies investigation.
The prostate cancer carcinogenesis is a complex 
process driven by genetic and epigenetic alterations [7, 
8]. Hormonal imbalance and lifestyle-related factors 
are considered as the major contributors to prostate 
cancer [5, 9]. Regarding to hormonal imbalance, 
5α-dihydrotestosterone (DHT), androgen receptor 
(AR), female hormones estrogens are critical targets for 
prostate cancer chemopreventions [9-11]. 5-α-reductase 
catalyzes the production of DHT. Then with increased 
androgenic activity, DHT activates multiple genes 
involved in carcinogenesis via AR [9-11]. Estrogen 
promoted the prostate cancer development by mediating 
estrogen receptors (ER) [12]. 5-α-reductase inhibitor 
Dutasteride, Finasteride, AR antagonist Flutamide, 
Bicalutamide and ER blocker Toremifene are investigated 
as chemoprevention agents for prostate cancer in clinical 
trials [2, 3, 13-17]. Due to the anti-oxidant and anti-
proliferation activity and the limited toxicities, natural 
food compounds Selenium, Vitamin E, soy diets, tomato 
and green tea have been considered as the ideal candidate 
chemoprevention agents for prostate cancer in clinical 
trials [8, 18-23]. 
However, clinical trials performed with these agents 
in patients with HGPIN showed varied results. Most 
of these agents only showed minor effects to prevent 
prostate cancer development in HGPIN patients, for 
instance the Selenium and Vitamin E Cancer Prevention 
Trial (SELECT) [24, 25]. Even higher prostate cancer 
prevalence was found in HGPIN patients after taking 
some agents, for example Flutamid and the combination 
of lycopene, selenium, and green tea catechins [14, 
26]. Moreover, it’s important to find the agents with 
satisfying preventative efficiency to improve the clinical 
benefits for HGPIN patients. But due to the absence of 
head-to-head trials, network meta-analysis using direct 
and indirect evidence to compare the relative efficacy of 
these candidate agents is needed. In this study, We aimed 
to evaluate these chemoprevention agents and find the 
agents with the most satisfying efficiency.we performed 
a pairwise meta-analysis to summarize the efficacy of 
candidate chemoprevention agent, and used adjusted 
indirect meta-analysis to compare the relative efficacy 
of these candidate chemoprevention agents. We aimed to 
systematically summarize the efficacy of pharmacological 
agents and natural food compounds for HGPIN patients 
and find the agents with the most satisfying efficiency. 
RESULTS
Characteristics of included trials
After removing duplicated literatures, unrelated 
literatures and some ineligible literatures, two 
investigators identified articles eligible for further review 
by screening titles and abstracts independently. Finally, we 
identified 13 literatures involved 3,020 patients eligible for 
analysis (Figure 1). Candidate chemoprevention agents 
used in these eligible studies included 5-α reductase 
inhibitor Dutasteride (n = 1), AR antagonist Flutamide 
(n = 1), Bicalutamide (n = 2), estrogen receptors blocker 
Toremifene (n = 2), micronutrient supplement Selenium 
(n = 1), green tea catechins (n = 2), Lycopene (n = 2), 
the natural food product combination (n = 2, Lycopene + 
Selenium + green tea catechins and soy protein + Vitamin 
E + Selenium). The details about the thirteen literatures 
are listed in Table 1. 
Risk of bias
No high risk of bias was assessed in these studies. 
The risk of bias evaluations for the included studies was 
summarized in Figure 2. 
Direct meta-analysis of the efficacy of 
chemoprevention agents for HGPIN
The pooled prostate cancer incidence in HGPIN 
patients received chemoprevention agents and patients not 
received chemoprevention agents were 25.7% and 31.5% 
respectively. The overall incidence of prostate cancer 
in HGPIN was slightly decreased by chemoprevention 
agents (RR = 0.92, 95% CI: 0.83-1.03, P = 0.183), with 
minor heterogeneity (I2 = 22.3%, x2 = 15.08, P = 0.237), 
but without statistic significance (Figure 3). Begg’s test 
and Egger’s test both showed no evidence of substantial 
publication bias (P = 0.721, P = 0.788). The funnel plot 
was shown in Figure 4.
Subgroup analysis showed that green tea catechins 
significantly decreased the prostate cancer in HGPIN 
patients (7.60% vs 23.1%, RR = 0.39, 95% CI: 0.16-10.97, 
P = 0.044), with moderate heterogeneity (I2 = 47.9%, x2 
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= 1.92, P = 0.166). Lycopene, Toremifene, Bicalutamide 
decreased the prostate cancer in HGPIN patients (13.0% 
vs 19.2% RR = 0.70, 95% CI: 0.27-1.85, 24.8% vs 32.0% 
RR = 0.91, 95% CI: 0.79-1.05, 7.2% vs 14.3% RR = 0.42, 
95% CI: 0.08-2.11 respectively), but without statistical 
significances. The natural food combination showed slight 
increased prostate cancer in HGPIN patients (7.60% vs 
23.1%, RR = 1.11, 95% CI: 0.77-1.58) without statistical 
significance.
Adjusted indirect meta-analysis of the efficacy of 
chemoprevention agents for HGPIN
The network is given in Figure 5. We compared 
each pair of chemoprevention agents using placebo 
as a data bridge head-to-head. The indirect estimates 
favor green tea catechins over other chemoprevention 
agents, and significantly when compared to natural food 
products combination (RR = 0.355, 95% CI: 0.134, 
0.934). Lycopene showed better chemoprevention 
effects in HGPIN patients than Dutasteride, natural food 
combination, Toremifene, Selenium and Flutamide, 
but without statistical significance. Regarding to 
the chemoprevention agents targeted on hormonal 
imbalance, the indirect estimates favor Bicalutamide 
over Dutasteride, Toremifene and Flutamide, but without 
statistical significance. Toremifene also showed better 
chemoprevention effects than Flutamide, but without 
statistical significance. All heterogeneity statistics are not 
significant at P = 0.05.
Figure 1: Flow diagram of study selection process.
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Table 2: Indirect comparison of chemoprevention agents under fixed effects
Table 1: Summary of clinical trials involved in the meta-analysis
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DISCUSSION
In this systematic review, we combined direct 
evidence from 13 randomized controlled trials comparing 
7 different interventions and reporting on 3,020 
participants with HGPIN to make observations regarding 
the potential efficacy of prostate cancer chemoprevention 
agents. The meta-analysis showed that the efficacy of 
prostate cancer chemoprevention agents is not satisfying, 
it only slightly decreased the prostate cancer and without 
significance. However, compared to other agents, green 
tea catechins showed promising benefits for HGPIN 
patients, and significantly better than the natural food 
product combination.
Our study extends findings from primary randomized 
controlled trials and systematic reviews. Most of the study 
for prostate cancer prevention focused on the observation 
or retrospective study to investigate the risk factors for 
prostate cancer, or the effects of candidate agents to 
prevent prostate cancer progression, recurrence and 
mortality. Chemoprevention agents targeted on pre-cancer 
patients to decrease prostate cancer risk is also important 
to improve the health outcomes. An ideal preventive 
agent should delay or reverse carcinogenesis effectively, 
Figure 2: Risk of bias evaluations.
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Figure 4: Funnel plot.
Figure 3: Forest plot for risk ratio confidence intervals of prostate cancer incidence in HGPIN patients. The red squares 
indicated the single risk ratios reported from each study. The black diamond squares indicated the pooled risk ratios from meta-analysis.
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at the same time, it should not cause any harm to healthy 
people, which raised the bar for chemoprevention 
research. Former studies showed that some 5-α reductase 
inhibitor showed significant effects to reduce the risk 
of prostate cancer, but with increased risk for high-
grade disease [27-29]. For another, HGPIN patients are 
at high risk to develop prostate cancer [5, 6], but these 
studies are performed on general risk population but not 
HGPIN patients. Clinical trials to investigate these agents 
and develop novel chemoprevention agents in HGPIN 
population were needed. In this study, we summarized the 
findings from primary randomized controlled trials to get a 
more clear data about chemoprevention of prostate cancer 
in HGPIN patients.
The chemoprevention agents summarized in this 
study are targeted on hormonal imbalance or diets, the two 
important contributors to prostate cancer [5, 9]. Agents 
targeted on hormonal imbalance summarized in this study 
include Dutasteride [13], Flutamide [14], Bicalutamide 
[16, 17] and Toremifene [3, 15]. The Dutasteride clinical 
trial involved in this study showed that Dutasteride did 
not decrease prostate cancer incidence but did not worsen 
the HGPIN [13]. In the Flutamide trial, no evidence of 
benefit was found [14]. The pooled results from meta-
analysis showed the potential of Bicalutamide to inhibit 
prostate cancer development, but without significance [16, 
17]. The pooled efficacy of Toremifene was also limited 
in HGPIN patients [3, 15]. However, the adjusted indirect 
analysis showed that Bicalutamide might have better 
clinical benefits for HGPIN patients than Dutasteride, 
Toremifene and Flutamide. This result might be related to 
the different mechanisms among these drugs. Bicalutamide 
and Flutamide are AR antagonists. AR plays a pivotal role 
in prostate cancer by transactivation of multiple genes 
involved in tumorigenesis [30]. Moreover, Bicalutamide 
was derived from flutamide by structural modification to 
increase the agonist properties against AR [31]. However, 
the limitation of these chemical drugs underscored the 
needs of other chemopreventive agents for HGPIN 
patients. 
Natural products such as vitamins, minerals, 
probiotics, herbal medicines showed potential cancer 
prevention effects with low toxicity profiles [32, 33]. 
“Food-based” prevention approaches such as green tea, 
soy product, lycopene, selenium included in this meta-
analysis are all reported to be associated with reduced risk 
of cancer. In our direct meta-analysis, subgroup analysis 
showed that only green tea catechins showed significant 
clinical benefits for HGPIN patients. In our indirect 
meta-analysis, the results favor green tea catechins over 
all other chemoprevention agents. Observation studies 
in Japan and China showed that green tea intake in diet 
might decrease the risk of localized and advanced prostate 
cancers [34-36]. But some studies showed no association 
between tea consumption and prostate cancer risk [37, 
38]. A recent meta-analysis did not support the conclusion 
that tea consumption could reduce prostate cancer risk 
neither [39]. The data used in this meta-analysis were 
extracted from cohort studies and case-control studies, 
but not randomized controlled trials. When they limited 
the analysis to case-control study, they found a protective 
effect for tea consumption against prostate cancer. Our 
Figure 5: The network in the adjusted indirect analysis. The full line indicates the direct analysis and the dotted line indicates 
the indirect analysis.
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results pooled results from randomized controlled trials 
supported the conclusion that green tea catechins was an 
efficient agent for HGPIN patients to prevent prostate 
cancer. (-)-epigallocatechin-3-gallate (EGCG) are the 
most abundant green tea catechins, comprising 50% to 
75% of the material in the investigational agent in the 
two trials [5, 8]. EGCG showed anticancer activity for 
prostate cancer in cell model, animals and human clinical 
trials [5, 8, 40]. EGCG can decreased androgen receptor 
(AR) and inhibit 5-a-reductase. It also showed the effects 
to inhibit proliferation, angiogenesis, apoptotic cell 
death and other cell activity through oncogenic signaling 
pathway such as NFκB/MAPK/IGFR/COX-2 [40]. Since 
carcinogenesis is a process with multiple stages and 
multiple factors involved, the synergistic effects of EGCG 
may contribute to the superior benefits of EGCG than 
other chemoprevention agents.
Our adjusted indirect meta-analysis showed that 
lycopene might have better chemoprevention effects in 
HGPIN patients than most of the other agents except green 
tea catechins and Bicalutamide, but without significance. 
Lycopene has been studies for a long time because of 
their efficacy to lower the risk of prostate cancer [41]. 
Between the two lycopene trials in this meta-analysis, the 
HGPIN patients were given the different dose, at 8 mg/
day in Mohanty’s study and 30mg/day in Gann’s study 
[20, 21]. But the lower dose showed the better clinical 
benefit. In the two natural production combination trails, 
each single components all have the potential to prevent 
prostate cancer, but the combination even worsen the 
prostate cancer incidence [24, 26]. The failure of high 
dose lycopene and the combination in Gontere’s study 
may due to the short time intervention, only 6 months. 
We performed a subgroup Meta-analysis to compare trials 
with 6 months intervention and that with more than 6 
month, and found no significant difference between them 
(Supplemental Figure 1). But this subgroup setting is not 
thorough due to the limited biological significance. Recent 
data showed that a high prostate cancer detection rate at 
early repeat biopsy (6 months) in men with HGPIN is 
common in several clinical trials, because prostate cancer 
has been already present at the initial HGPIN diagnosis 
[13]. This may help to explain the reason why 6 month 
intervention showed limited chemoprevention effects. 
Larger, longer and précised design trials are needed to 
figure out the reason. 
There are limitations in this study. A recent study to 
systematically summarize dietary, nutritional, and physical 
activity interventions for the prevention of prostate cancer 
progression and mortality failed to get a conclusion. The 
author considered limitation patients numbers, risk of bias, 
underpowered, inadequately reported, short duration or 
measured surrogate outcomes of unproven relationship to 
mortality or disease progression as the potential reasons 
[42]. These issues may be common in modification 
interventions. Although we didn’t find significant risk 
bias in the analysis, the above reasons may exist. HGPIN 
may be more prevalent in African American men even 
after controlling other factors [43]. However most of the 
patients recruited in these trials are white men. Prostate 
cancer incidence was significantly higher in plurifocal 
HGPIN patients than monofocal HGPIN patients [44]. The 
number of core samples with HGPIN increase is in parallel 
with the risk for prostate cancer [45]. Over diagnosis of 
HGPIN influenced the results from the clinical trials 
taking candidate agents to prevent development of prostate 
cancer [46]. However in this meta-analysis, we didn’t 
analysis the race, histopathology status, the number of 
core samples and the over diagnosis issues about HGPIN, 
which are potential to cause the bias of the results. Due 
to the limited data, we only assess the prostate cancer 
incidence but not other indicators such as the disease 
free survival, the PSA changes, and adverse effects as 
additional endpoint. 
In conclusion, this study didn’t show a significant 
effect of the chemoprevention agents to prevent prostate 
cancer development in HGPIN patients. The direct and 
indirect meta-analysis demonstrated that green tea green 
tea catechins significantly inhibit prostate cancer in 
HGPIN patients and are better than other chemoprevention 
agents for prostate cancer. The results of this study have 
implication for the prostate cancer prevention and support 
the future clinical study with green tea catechins for 
HGPIN patients. 
MATERIALS AND METHODS
Search strategy and searches
Literature searches were conducted in PubMed, 
EMBASE and Cochrane library according to Cochrane 
guidelines before January 31st, 2017 [47]. Search key terms 
included high-grade prostatic intraepithelial neoplasia, 
chemoprevention, prostate cancer and randomized 
controlled trial. We also manually searched references in 
identified studies in case of missing trials. 
Study selection
Randomized controlled trials that enrolled high-
grade prostatic intraepithelial neoplasia patients to receive 
any intervention for prostate cancer chemoprevention 
were included. The primary outcome assessed in this 
study is the prevalence of prostate cancer in high-
grade prostatic intraepithelial neoplasia patient after 
chemoprevention intervention. The eligible studies should 
report the incidence of prostate cancer development after 
the intervention. The risk of bias was assessed by three 
reviewers using the Cochrane Collaboration’s tool [48]. 
The risk of bias was graded as high, low, or unclear.
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Statistical method
Direct meta-analysis was performed with fixed 
effects model to estimate pooled relative ratios and 95% 
confidence intervals incorporating heterogeneity within 
and between studies. Subgroup analysis was based 
on the different chemoprevention agents. Statistical 
heterogeneity was assessed with I2 statistic, with values 
over 50% indicating substantial heterogeneity. Publication 
bias was analyzed by both Begg’s and Egger’s regression 
asymmetry test, and visually evaluated using the funnel 
plot. 
Adjusted indirect comparisons were performed to 
estimate the relative ratio between different candidate 
chemoprevention agents using placebo as a data bridge. 
The adjusted indirect meta-analysis developed by Bucher 
et al. allows for the comparison of two treatments by 
comparing each of the interventions with a common 
comparator [49]. The “indirect” command implemented 
in Stata was employed to convert the summary estimates 
(log RRs) and measures of uncertainty (variances) from 
the meta-analyses into an RR and 95% CI representing 
the difference between each two chemoprevention agents 
[50].  Stata Statistical Software (version 14.0 Stata Corp., 
College Station, TX, USA) was used for all analyses. A 
two-sided P value ≤ 0.05 was considered as statistically 
significant. The data set and command used in Stata are 
list in Supplemental Table 1.
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